Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: F7

Gene summary for F7

Gene summary.

Gene information	Species	Human
	Gene symbol	F7
	Gene ID	2155
	Gene name	coagulation factor VII
	Gene Alias	SPCA
	Cytomap	13q34
	Gene Type	protein-coding
	GO ID	GO:0001101
	UniProtAcc	P08709

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2155	F7	HCC1_Meng	Human	Liver	HCC	9.89e-73	3.64e-01	0.0246
2155	F7	HCC1	Human	Liver	HCC	1.75e-25	4.37e+00	0.5336
2155	F7	HCC2	Human	Liver	HCC	2.13e-11	3.67e+00	0.5341
2155	F7	Pt14.a	Human	Liver	HCC	1.22e-03	2.45e-01	0.0169
2155	F7	S014	Human	Liver	HCC	2.61e-19	1.05e+00	0.2254
2155	F7	S015	Human	Liver	HCC	2.21e-30	1.78e+00	0.2375
2155	F7	S016	Human	Liver	HCC	2.90e-24	9.09e-01	0.2243
2155	F7	S028	Human	Liver	HCC	9.68e-10	3.41e-01	0.2503
2155	F7	S029	Human	Liver	HCC	1.14e-06	3.03e-01	0.2581

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Liver		HCC: Hepatocellular carcinoma
Liver		NAFLD: Non-alcoholic fatty liver disease

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000974325	Oral cavity	NEOLP	response to carbohydrate	45/2005	253/18723	4.43e-04	4.00e-03	45
GO:00311092	Oral cavity	NEOLP	microtubule polymerization or depolymerization	26/2005	122/18723	4.52e-04	4.06e-03	26
GO:003428425	Oral cavity	NEOLP	response to monosaccharide	41/2005	225/18723	4.69e-04	4.20e-03	41
GO:005149417	Oral cavity	NEOLP	negative regulation of cytoskeleton organization	32/2005	163/18723	5.07e-04	4.48e-03	32
GO:005068631	Oral cavity	NEOLP	negative regulation of mRNA processing	10/2005	29/18723	5.71e-04	4.96e-03	10
GO:001063932	Oral cavity	NEOLP	negative regulation of organelle organization	57/2005	348/18723	7.37e-04	6.03e-03	57
GO:000974624	Oral cavity	NEOLP	response to hexose	39/2005	219/18723	1.00e-03	7.68e-03	39
GO:007132223	Oral cavity	NEOLP	cellular response to carbohydrate stimulus	31/2005	163/18723	1.07e-03	8.08e-03	31
GO:005105113	Oral cavity	NEOLP	negative regulation of transport	72/2005	470/18723	1.14e-03	8.49e-03	72
GO:007267331	Oral cavity	NEOLP	lamellipodium morphogenesis	7/2005	17/18723	1.18e-03	8.72e-03	7
GO:190274522	Oral cavity	NEOLP	positive regulation of lamellipodium organization	11/2005	37/18723	1.26e-03	9.21e-03	11
GO:007133323	Oral cavity	NEOLP	cellular response to glucose stimulus	29/2005	151/18723	1.30e-03	9.44e-03	29
GO:000167824	Oral cavity	NEOLP	cellular glucose homeostasis	32/2005	172/18723	1.31e-03	9.48e-03	32
GO:007133123	Oral cavity	NEOLP	cellular response to hexose stimulus	29/2005	153/18723	1.60e-03	1.12e-02	29
GO:004511621	Oral cavity	NEOLP	protein neddylation	7/2005	18/18723	1.75e-03	1.21e-02	7
GO:007132623	Oral cavity	NEOLP	cellular response to monosaccharide stimulus	29/2005	154/18723	1.78e-03	1.22e-02	29
GO:000703022	Oral cavity	NEOLP	Golgi organization	29/2005	157/18723	2.40e-03	1.53e-02	29
GO:00310572	Oral cavity	NEOLP	negative regulation of histone modification	12/2005	46/18723	2.66e-03	1.66e-02	12
GO:19019833	Oral cavity	NEOLP	regulation of protein acetylation	17/2005	77/18723	2.80e-03	1.73e-02	17
GO:00070203	Oral cavity	NEOLP	microtubule nucleation	10/2005	35/18723	2.88e-03	1.77e-02	10

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa046104	Liver	HCC	Complement and coagulation cascades	57/4020	86/8465	3.19e-04	1.45e-03	8.04e-04	57
hsa046105	Liver	HCC	Complement and coagulation cascades	57/4020	86/8465	3.19e-04	1.45e-03	8.04e-04	57

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SNV

Missense_Mutation

novel

c.308N>A

p.Ser103Tyr

p.S103Y

P08709

protein_coding

tolerated(0.17)

benign(0.028)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

SNV

Missense_Mutation

c.729N>G

p.Ile243Met

p.I243M

P08709

protein_coding

deleterious(0.04)

benign(0.157)

TCGA-AN-A0AM-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SNV

Missense_Mutation

novel

c.1132N>A

p.Gly378Arg

p.G378R

P08709

protein_coding

tolerated(0.22)

benign(0)

TCGA-AR-A2LJ-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

SNV

Missense_Mutation

rs749760143

c.973N>A

p.Glu325Lys

p.E325K

P08709

protein_coding

tolerated(0.05)

probably_damaging(0.933)

TCGA-C8-A1HM-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

doxorubicin

insertion

Frame_Shift_Ins

novel

c.731_732insGGGAAAATGGGCAGGTCAGC

p.Asn244LysfsTer28

p.N244Kfs*28

P08709

protein_coding

TCGA-AN-A0AM-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

insertion

Frame_Shift_Ins

novel

c.757_758insGCAA

p.His253ArgfsTer29

p.H253Rfs*29

P08709

protein_coding

TCGA-BH-A0HY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

taxotere

insertion

In_Frame_Ins

novel

c.759_760insCCCAAGGCCGAATTGTGGGGGGCAAGG

p.His253_Cys254insProLysAlaGluLeuTrpGlyAlaArg

p.H253_C254insPKAELWGAR

P08709

protein_coding

TCGA-BH-A0HY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

taxotere

SNV

Missense_Mutation

c.475N>C

p.Glu159Gln

p.E159Q

P08709

protein_coding

deleterious(0.04)

benign(0.115)

TCGA-DR-A0ZM-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unspecific

Cisplatin

SNV

Missense_Mutation

novel

c.348N>C

p.Gln116His

p.Q116H

P08709

protein_coding

deleterious(0.02)

probably_damaging(0.961)

TCGA-EA-A3HU-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

SNV

Missense_Mutation

c.160N>A

p.Val54Ile

p.V54I

P08709

protein_coding

tolerated(0.2)

benign(0.01)

TCGA-AA-3811-01

Colorectum

colon adenocarcinoma

Female

>=65

III/IV

Unknown

Page: 1 2 3 4 5 6 7

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE		Vatreptacog alfa (activated)
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE		Factor viia
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE		Recombinant factor VIIa PEGylated liposomal
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE		F-7TG
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE		BAX-817
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE	inhibitor	178103166
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE		CB-813
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE		Activated recombinant FVII-albumin fusion protein
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE	inhibitor	252166701
2155	F7	ENZYME, DRUGGABLE GENOME, PROTEASE		Eptacog alfa intravenous

Page: 1